Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Authors:
- Giacomo GrassiGGGiacomo Grassi
- Chiara CecchelliCCChiara Cecchelli
- Luisa VignozziLVLuisa Vignozzi
- Silvia PaciniSPSilvia Pacini
Open Access
- 1 January 2021
- journal article
- review article
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 12, 695-706
Abstract
Treatment-resistance is a frequent condition for obsessive-compulsive disorder (OCD). Over the past decades, a lot of effort has been made to address this issue, and several augmentation strategies of serotonergic drugs have been investigated. Antidopaminergic drugs are considered the first choice as augmentation strategy for treatment-resistant OCD patients, but they seem to work only for a subset of patients, and none of them have been officially approved for OCD. Recently, the role of glutamate and inflammation in OCD pathophysiology clearly emerged, and this has led to several investigations on glutamatergic and anti-inflammatory agents. Results seem promising but still inconclusive. Probiotic interventions (considered to modulate the immune systems and the brain activity) are gaining attention in several psychiatric fields but are still at their early stages in the OCD field. Research on new treatment approaches for OCD is moving forward, and more than one hundred interventional trials are ongoing around the world. While the vast majority of these trials involve neuromodulation and psychotherapeutic approaches, only a small proportion (around 20%) involve the investigation of new pharmacological approaches (tolcapone, nabilone, psilocybin, troriluzole, nitrous oxide, rituximab, naproxen, and immunoglobulins). Here, we provide a comprehensive review of investigational and experimental drugs to treat OCD.Keywords
This publication has 124 references indexed in Scilit:
- Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled studyJournal of Affective Disorders, 2012
- Sarcosine Therapy for Obsessive Compulsive DisorderJournal of Clinical Psychopharmacology, 2011
- Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicityFree Radical Biology and Medicine, 2010
- A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 2010
- Neural concomitants of immunity—Focus on the vagus nerveNeuroImage, 2009
- Prevalence of mood and anxiety disorders in women with systemic lupus erythematosusArthritis Care & Research, 2009
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMolecular Psychiatry, 2008
- Anterior Cingulate Glutamate–Glutamine Levels Predict Symptom Severity in Women With Obsessive–Compulsive DisorderAustralian & New Zealand Journal of Psychiatry, 2008
- Cyclooxygenase-2 Inhibition Protects Cultured Cerebellar Granule Neurons from Glutamate-Mediated Cell DeathJournal of Neurotrauma, 2002
- Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson??s DiseaseClinical Pharmacokinetics, 2002